169 related articles for article (PubMed ID: 17197042)
1. Development and validation of a non-radioactive DNA polymerase assay for studying cytomegalovirus resistance to foscarnet.
Ducancelle A; Alain S; Petit F; Sanson Le Pors MJ; Mazeron MC
J Virol Methods; 2007 May; 141(2):212-5. PubMed ID: 17197042
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic characterisation of cytomegalovirus DNA polymerase: a method to study cytomegalovirus isolates resistant to foscarnet.
Ducancelle A; Gravisse J; Alain S; Fillet AM; Petit F; Pors MJ; Mazeron MC
J Virol Methods; 2005 May; 125(2):145-51. PubMed ID: 15794984
[TBL] [Abstract][Full Text] [Related]
3. [A novel colorimetric test to study the susceptibility of human cytomegalovirus DNA polymerase to foscarnet].
Ducancelle A; Alain S; Scieux C; Fillet AM; Petit F; Sanson-Le Pors MJ; Mazeron MC
Pathol Biol (Paris); 2005; 53(8-9):551-5. PubMed ID: 16084026
[TBL] [Abstract][Full Text] [Related]
4. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet.
Ducancelle A; Champier G; Alain S; Petit F; Le Pors MJ; Mazeron MC
Antivir Ther; 2006; 11(4):537-40. PubMed ID: 16856628
[TBL] [Abstract][Full Text] [Related]
5. Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet.
Bonnafous P; Naesens L; Petrella S; Gautheret-Dejean A; Boutolleau D; Sougakoff W; Agut H
Antivir Ther; 2007; 12(6):877-88. PubMed ID: 17926642
[TBL] [Abstract][Full Text] [Related]
6. Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity.
Martin M; Azzi A; Lin SX; Boivin G
Antivir Ther; 2010; 15(4):579-86. PubMed ID: 20587851
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations.
Scott GM; Isaacs MA; Zeng F; Kesson AM; Rawlinson WD
J Med Virol; 2004 Sep; 74(1):85-93. PubMed ID: 15258973
[TBL] [Abstract][Full Text] [Related]
8. Ganciclovir resistance mutations in UL97 and UL54 genes of Human cytomegalovirus isolates resistant to ganciclovir.
Foulongne V; Turrière C; Diafouka F; Abraham B; Lastere S; Segondy M
Acta Virol; 2004; 48(1):51-5. PubMed ID: 15230476
[TBL] [Abstract][Full Text] [Related]
9. Contrasting effects of W781V and W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility.
Piret J; Goyette N; Eckenroth BE; Drouot E; Götte M; Boivin G
J Virol; 2015 Apr; 89(8):4636-44. PubMed ID: 25673718
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
Fischer L; Laib Sampaio K; Jahn G; Hamprecht K; Göhring K
Antiviral Res; 2013 Dec; 100(3):575-7. PubMed ID: 24120366
[TBL] [Abstract][Full Text] [Related]
11. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.
Weinberg A; Jabs DA; Chou S; Martin BK; Lurain NS; Forman MS; Crumpacker C; ;
J Infect Dis; 2003 Mar; 187(5):777-84. PubMed ID: 12599051
[TBL] [Abstract][Full Text] [Related]
12. Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis.
Andouard D; Mazeron MC; Ligat G; Couvreux A; Pouteil-Noble C; Cahen R; Yasdanpanah Y; Deering M; Viget N; Alain S; Hantz S
Antiviral Res; 2016 May; 129():115-119. PubMed ID: 26872863
[TBL] [Abstract][Full Text] [Related]
13. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.
Tchesnokov EP; Gilbert C; Boivin G; Götte M
J Virol; 2006 Feb; 80(3):1440-50. PubMed ID: 16415021
[TBL] [Abstract][Full Text] [Related]
14. Differential impact of various substitutions at codon 715 in region II of HSV-1 and HCMV DNA polymerases.
Zarrouk K; Zhu X; Goyette N; Piret J; Shi R; Boivin G
Antiviral Res; 2021 Apr; 188():105046. PubMed ID: 33588012
[TBL] [Abstract][Full Text] [Related]
15. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus.
Chou S; Lurain NS; Thompson KD; Miner RC; Drew WL
J Infect Dis; 2003 Jul; 188(1):32-9. PubMed ID: 12825168
[TBL] [Abstract][Full Text] [Related]
16. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Cihlar T; Fuller MD; Cherrington JM
J Virol; 1998 Jul; 72(7):5927-36. PubMed ID: 9621055
[TBL] [Abstract][Full Text] [Related]
17. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.
Gilbert C; Boivin G
Antimicrob Agents Chemother; 2005 Dec; 49(12):4860-6. PubMed ID: 16304146
[TBL] [Abstract][Full Text] [Related]
18. Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model.
Hantz S; Cotin S; Borst E; Couvreux A; Salmier A; Garrigue I; Merville P; Mengelle C; Attal M; Messerle M; Alain S
Antiviral Res; 2013 Apr; 98(1):130-4. PubMed ID: 23415883
[TBL] [Abstract][Full Text] [Related]
19. Foscarnet resistance mutations mapping to atypical domains of the cytomegalovirus DNA polymerase gene.
Chou S
Antiviral Res; 2017 Feb; 138():57-60. PubMed ID: 27940027
[TBL] [Abstract][Full Text] [Related]
20. 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
Schnute ME; Cudahy MM; Brideau RJ; Homa FL; Hopkins TA; Knechtel ML; Oien NL; Pitts TW; Poorman RA; Wathen MW; Wieber JL
J Med Chem; 2005 Sep; 48(18):5794-804. PubMed ID: 16134946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
